WO2004087660A1 - A novel process for amorphous form of donepezil hydrochloride - Google Patents
A novel process for amorphous form of donepezil hydrochloride Download PDFInfo
- Publication number
- WO2004087660A1 WO2004087660A1 PCT/IN2003/000136 IN0300136W WO2004087660A1 WO 2004087660 A1 WO2004087660 A1 WO 2004087660A1 IN 0300136 W IN0300136 W IN 0300136W WO 2004087660 A1 WO2004087660 A1 WO 2004087660A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- donepezil hydrochloride
- novel process
- alcohol
- amorphous
- solvents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Definitions
- the present invention provides a novel process for the preparation of donepezil hydrochloride.
- the object of the present invention is to provide a novel process for the preparation of the amorphous of donepezil hydrochloride.
- the amorphous donepezil hydrochloride is characterized by having broad x-ray diffraction spectrum as in figure 1.
- One aspect of the present invention provides a process for the preparation of amorphous donepezil hydrochloride.
- Amorphous donepezil hydrochloride is prepared by dissolving donepezil hydrochloride in a mixture comprising an alcoholic solvent and a chlorinated solvent; and removing the solvents from the solution.
- the solvents can be removed by techniques such as vacuum drying, lyophilization, distillation under vacuum, freeze drying, spray drying, etc.
- the alcoholic solvent is selected from the group consisting of methanol, ethanol, isopropyl alcohol, tert-butyl alcohol and n-butyl alcohol. Methanol is a preferred solvent.
- the suitable chlorinated solvents are chloroform, methylene dichloride, carbontetrachloride and ethylene dichloride. Methylene dichloride and chloroform are preferred solvents.
- Figure 1 is a x-ray powder diffraction spectrum of amorphous donepezil hydrochloride. x-Ray powder diffraction spectrum was measured on a Siemens D5000 x- ray powder diffractometer having a copper-K ⁇ radiation.
- Example 1 Donepezil hydrochloride (10 gm, obtained by the process described in example 4 of EP 296560) is dissolved in the mixture of methanol (50 ml) and chloroform (50 ml). The solution is subjected to vacuum drying at about 40°C for 10 hours to give 9.1 gm of amorphous donepezil hydrochloride.
- Example 2 Example 1 is repeated by subjecting the solution to spray drying instead of vacuum drying using nitrogen gas to give amorphous donepezil hydrochloride.
- Example 3 Crystalline donepezil hydrochloride (10 gm) is dissolved in the mixure of ethanol (60 ml) and chloroform (50 ml). The solution is subjected to vacuum drying at about 45°C for 9 hours to give 9.2 gm of amorphous donepezil hydrochloride.
- Example 4 Example 3 is repeated by subjecting the solution to spray drying using nitrogen gas instead of vacuum drying to give amorphous donepezil hydrochloride.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a novel process for the preparation of donepezil hydrochloride.
Description
A NOVEL PROCESS FOR AMORPHOUS FORM OF DONEPEZIL
HYDROCHLORIDE
FIELD OF THE INVENTION
The present invention provides a novel process for the preparation of donepezil hydrochloride.
BACKGROUND OF THE INVENTION
Donepezil hydrochloride of formula (1):
or 2,3-Dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H- inden-1-one hydrochloride is useful for prevention and treatment of alzheimer disease. The therapeutic uses of donepezil hydrochloride and related compounds are disclosed in EP 296560. Amorphous form of donepezil hydrochloride is mentioned in US 6,140,321.
We have discovered a simple novel process for the preparation of amorphous form of donepezil hydrochloride.
The object of the present invention is to provide a novel process for the preparation of the amorphous of donepezil hydrochloride.
DETAILED DESCRIPTION OF THE INVENTION
The amorphous donepezil hydrochloride is characterized by having broad x-ray diffraction spectrum as in figure 1.
One aspect of the present invention provides a process for the preparation of amorphous donepezil hydrochloride. Amorphous donepezil hydrochloride is prepared by dissolving donepezil hydrochloride in a mixture comprising an alcoholic solvent and a chlorinated solvent; and removing the solvents from the solution. The solvents can be removed by techniques such as vacuum drying, lyophilization, distillation under vacuum, freeze drying, spray drying, etc. The alcoholic solvent is selected from the group consisting of methanol, ethanol, isopropyl alcohol, tert-butyl alcohol and n-butyl alcohol. Methanol is a preferred solvent.The suitable chlorinated solvents are chloroform, methylene dichloride, carbontetrachloride and ethylene dichloride. Methylene dichloride and chloroform are preferred solvents.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1 is a x-ray powder diffraction spectrum of amorphous donepezil hydrochloride. x-Ray powder diffraction spectrum was measured on a Siemens D5000 x- ray powder diffractometer having a copper-Kα radiation.
The following examples further illustrate the invention.
Example 1 Donepezil hydrochloride (10 gm, obtained by the process described in example 4 of EP 296560) is dissolved in the mixture of methanol (50 ml) and chloroform (50 ml). The solution is subjected to vacuum drying at about 40°C for 10 hours to give 9.1 gm of amorphous donepezil hydrochloride.
Example 2 Example 1 is repeated by subjecting the solution to spray drying instead of vacuum drying using nitrogen gas to give amorphous donepezil hydrochloride.
Example 3
Crystalline donepezil hydrochloride (10 gm) is dissolved in the mixure of ethanol (60 ml) and chloroform (50 ml). The solution is subjected to vacuum drying at about 45°C for 9 hours to give 9.2 gm of amorphous donepezil hydrochloride.
Example 4 Example 3 is repeated by subjecting the solution to spray drying using nitrogen gas instead of vacuum drying to give amorphous donepezil hydrochloride.
Claims
1. A process for preparation of amorphous donepezil hydrochloride, which comprises: a) dissolving donepezil hydrochloride in a mixture of an alcohol and a chlorinated solvent; and b) removing the solvents from the solution; wherein the alcohol is selected from the group consisting of methanol, ethanol, isopropyl alcohol, tert-butyl alcohol and n-butyl alcohol and the chlorinated solvent is selected from the group consisting of chloroform, methylene dichloride, carbontetrachloride and ethylene dichloride.
2. A process according to claim 1 , wherein the solvents are removed by vacuum drying.
3. A process according to claim 3, wherein the solvents are removed by spray drying.
4. A process according to claim 3, wherein the alcohol is methanol or ethanol and the chlorinated solvent is methylene dichloride or chloroform.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003230195A AU2003230195A1 (en) | 2003-04-02 | 2003-04-02 | A novel process for amorphous form of donepezil hydrochloride |
| US10/509,952 US7772399B2 (en) | 2003-04-02 | 2003-04-02 | Process for amorphous form of donepezil hydrochloride |
| PCT/IN2003/000136 WO2004087660A1 (en) | 2003-04-02 | 2003-04-02 | A novel process for amorphous form of donepezil hydrochloride |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2003/000136 WO2004087660A1 (en) | 2003-04-02 | 2003-04-02 | A novel process for amorphous form of donepezil hydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004087660A1 true WO2004087660A1 (en) | 2004-10-14 |
Family
ID=33104983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2003/000136 WO2004087660A1 (en) | 2003-04-02 | 2003-04-02 | A novel process for amorphous form of donepezil hydrochloride |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US7772399B2 (en) |
| AU (1) | AU2003230195A1 (en) |
| WO (1) | WO2004087660A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007037932A1 (en) | 2007-08-11 | 2009-02-12 | Alfred E. Tiefenbacher Gmbh & Co.Kg | Donepezil hydrochloride in amorphous form containing tablet |
| US7592459B2 (en) | 2004-09-29 | 2009-09-22 | Chemagis Ltd. | Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride |
| US8530488B2 (en) | 2007-10-24 | 2013-09-10 | Generics [Uk] Limited | Crystalline forms of bosentan |
| US8664390B2 (en) | 2007-06-29 | 2014-03-04 | Generics (Uk) Limited | Process for the introduction of hydroxyethoxy side chain in bosentan |
| US8785461B2 (en) | 2008-02-08 | 2014-07-22 | Generics [Uk] Limited | Process for preparing bosentan |
| US8975402B2 (en) | 2008-11-03 | 2015-03-10 | Generics [Uk] Limited | HPLC method for the analysis of bosetan and related substances and use of these substances as reference standards and markers |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006063025A1 (en) * | 2004-12-07 | 2006-06-15 | Nektar Therapeutics | Stable non-crystalline formulation comprising donepezil |
| HU227474B1 (en) * | 2005-12-20 | 2011-07-28 | Richter Gedeon Nyrt | Process for industrial scale production of high purity donepezil hydrochloride polymorph i. |
| WO2007108011A2 (en) * | 2006-03-20 | 2007-09-27 | Ind-Swift Laboratories Limited | Process for the preparation of highly pure donepezil |
| EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985864A (en) * | 1996-06-07 | 1999-11-16 | Eisai Co., Ltd. | Polymorphs of donepezil hydrochloride and process for production |
| EP1048653A1 (en) * | 1997-12-05 | 2000-11-02 | Eisai Co., Ltd. | Donepezil polycrystals and process for producing the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI95572C (en) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| US6649765B1 (en) * | 2003-02-12 | 2003-11-18 | Usv Limited, Bsd Marg. | Process for the preparation of 1-benzyl-4(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCL) |
| US7186842B2 (en) * | 2003-02-12 | 2007-03-06 | Usv, Ltd. | Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof |
-
2003
- 2003-04-02 US US10/509,952 patent/US7772399B2/en not_active Expired - Fee Related
- 2003-04-02 AU AU2003230195A patent/AU2003230195A1/en not_active Abandoned
- 2003-04-02 WO PCT/IN2003/000136 patent/WO2004087660A1/en not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985864A (en) * | 1996-06-07 | 1999-11-16 | Eisai Co., Ltd. | Polymorphs of donepezil hydrochloride and process for production |
| EP1048653A1 (en) * | 1997-12-05 | 2000-11-02 | Eisai Co., Ltd. | Donepezil polycrystals and process for producing the same |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7592459B2 (en) | 2004-09-29 | 2009-09-22 | Chemagis Ltd. | Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride |
| US8664390B2 (en) | 2007-06-29 | 2014-03-04 | Generics (Uk) Limited | Process for the introduction of hydroxyethoxy side chain in bosentan |
| DE102007037932A1 (en) | 2007-08-11 | 2009-02-12 | Alfred E. Tiefenbacher Gmbh & Co.Kg | Donepezil hydrochloride in amorphous form containing tablet |
| US8530488B2 (en) | 2007-10-24 | 2013-09-10 | Generics [Uk] Limited | Crystalline forms of bosentan |
| US8785461B2 (en) | 2008-02-08 | 2014-07-22 | Generics [Uk] Limited | Process for preparing bosentan |
| US8975402B2 (en) | 2008-11-03 | 2015-03-10 | Generics [Uk] Limited | HPLC method for the analysis of bosetan and related substances and use of these substances as reference standards and markers |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050222208A1 (en) | 2005-10-06 |
| AU2003230195A1 (en) | 2004-10-25 |
| US7772399B2 (en) | 2010-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2247113C2 (en) | Method of preparing amorphous atorvastatine | |
| EP2540704B1 (en) | Benethamine salt forms of atorvastatin | |
| BG61323B2 (en) | Piperidine derivatives, its preparation and its use as medicaments | |
| WO2004087660A1 (en) | A novel process for amorphous form of donepezil hydrochloride | |
| AU763523B2 (en) | Synthesis of histamine dihydrochloride | |
| JPH11506761A (en) | Triterpene | |
| US20080114173A1 (en) | Crystalline Form of Donepezil Hydrochloride | |
| HUE028620T2 (en) | Salt and solvates of a tetrahydroisoquinoline derivative | |
| WO2012131707A2 (en) | Novel crystalline form of bortezomib, process for the preparation and pharmaceutical composition thereof | |
| EP0415522B1 (en) | Process for reducing the crystal size of ondansetron hydrochloride dihydrate | |
| CA2508871C (en) | Crystalline form f of atorvastatin hemi-calcium salt | |
| WO2004092137A1 (en) | Novel crystalline forms of donepezil hydrochloride | |
| CA2410227A1 (en) | Crystal modification of fexofenadine | |
| AU2001265377A1 (en) | Crystal modification of fexofenadine | |
| WO2002053135A1 (en) | Amlodipine free base | |
| WO2007132472A1 (en) | A crystalline form b4 of atorvastatin magnesium and a process thereof | |
| WO2005123721A2 (en) | Amorphous and polymorphic forms of candesartan cilexetil | |
| WO2004087681A1 (en) | A novel amorphous form of valsartan | |
| AU2001283119A1 (en) | Polymorphs of zaleplon and methods for the preparation thereof | |
| EP1587792B1 (en) | Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof | |
| WO2005019199A1 (en) | Amorphous duloxetine hydrochloride | |
| KR100781420B1 (en) | Crystalline forms of [r-r*,r*]-2-4-fluorophenyl-beta,delta-dihydroxy-5-1-methylethyl-3-phenyl-4-[phenylaminocarbonyl]-1h-pyrrole-1-heptanoic acid | |
| US20050143445A1 (en) | Novel crystalline forms of levetiracetam | |
| WO2004099183A1 (en) | Novel polymorphs of pantoprazole sodium | |
| CA2448279A1 (en) | Process for preparing sertraline hydrochloride polymorphic form ii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 1370/CHENP/2003 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10509952 Country of ref document: US |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: JP |